- Home
- PAVM vs GTBP Comparison
PAVM vs GTBP Comparison
Compare PAVM & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | GTBP |
|---|---|---|
| Founded | 2014 | 1965 |
| Country | United States | United States |
| Employees | 107 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 12.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | PAVM | GTBP |
|---|---|---|
| Price | $9.10 | $0.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $510.00 | N/A |
| AVG Volume (30 Days) | 14.0K | ★ 653.6K |
| Earning Date | 05-14-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $450.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.39 |
| 52 Week High | $28.44 | $3.73 |
Technical Indicators
Market Signals| Indicator | PAVM | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 43.55 |
| Support Level | $8.43 | $0.40 |
| Resistance Level | $9.26 | $0.59 |
| Average True Range (ATR) | 0.55 | 0.03 |
| MACD | -0.23 | 0.01 |
| Stochastic Oscillator | 8.85 | 50.00 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.